Today is a historic day for dementia research with the US Food and Drug Administration (FDA) announcing the first (conditional) licence of a new drug for Alzheimer’s disease in a generation.
At Alzheimer’s Research UK, we are committed to finding treatments that slow or stop the diseases that cause dementia.
We won’t stop until we find them.
When someone receives a diagnosis of dementia, little is known about how their condition will progress and affect that individual over time. This is because dementia affects every person differently, with a number of factors influencing progression such as having other health conditions, our level of cognitive reserve and whether a person takes medications to treat other conditions.
More than a quarter of us own and use a wearable device. But what if some of the data they’re collecting could help scientists identify who was in the very early stages of a disease like Alzheimer’s, even before symptoms show?
It turns out that risk genes are a really important piece of the puzzle that helps us build our understanding of how a disease progresses.
Despite delays in recruitment to face-to-face dementia research studies, volunteer enrolment onto studies hosted by Join Dementia Research is at an all-time high since the service launched in 2015.
Alzheimer’s Research UK recently awarded a £96,000 grant to Prof Kevin Morgan at the University of Nottingham to maintain and expand his large collection of DNA samples. This is to ensure he can continue his important research into the genetics of Alzheimer’s disease.
Prof Katie Lunnon, the new Chair of our Grant Review Board, explains why we are urgently prioritising funding for early career dementia researchers.
It won’t come as a surprise that 2020 was a challenging year for dementia research.
But scientists have been working hard to overcome the challenges, and are continuing to make discoveries that will ultimately mean more lives free from the impact of dementia.
COVID-19 changed the course of this year in a way that nobody could have predicted. Our thoughts are with the individuals and families who have been directly affected by the virus and the medical, care and other key workers who have done so much to support us all through a very difficult year. Here at…